References
- De Fontbrune FS, Moignet A, Beaupain B, et al. Severe chronic primary neutropenia in adults: report on a series of 108 patients. Blood. 2015;126(14):1643–1650. doi:10.1182/blood-2015-03-634493
- Papadaki HA, Pontikoglou C. Pathophysiologic mechanisms, clinical features and treatment of idiopathic neutropenia. Expert Rev Hematol. 2008;1(2):217–229. doi:10.1586/17474086.1.2.217
- Dale David C, Bolyard AA. An update on the diagnosis and treatment of chronic idiopathic neutropenia. CurrOpinHematol. 2017;24(1):46–53.
- Peter EN, Daleb D C. Evaluation and management of patients with isolated neutropenia. Semin Hematol. 2013;50(3):198–206.
- Koumaki V, Damianaki A, Ximeri M, et al. Pro-inflammatory bone marrow milieu in patients with chronic idiopathic neutropenia is associated with impaired local production of interleukin-10. Br J Haematol. 2006;135(4):570–573. doi:10.1111/j.1365-2141.2006.06345.x
- Fioredda F, Skokowa J, Tamary H, et al. The European Guidelines on Diagnosis and management of neutropenia in adults and children: a consensus between the European Haematology Association and the EuNet-INNOCHRON COST action. Hemasphere. 2023;7(4):e872. doi:10.1097/HS9.0000000000000872
- Zhou Q, Yang D, Ombrello AK, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med. 2014;370(10):911–920. doi:10.1056/NEJMoa1307361
- Navon Elkan P, Pierce SB, Segel R, et al. Mutant adenosine deaminase 2 in a polyarteritisnodosavasculopathy. N Engl J Med. 2014;370(10):921–931. doi:10.1056/NEJMoa1307362
- Caorsi R, Penco F, Grossi A, et al. ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritisnodosa and stroke: a multicentre national study. Ann Rheum Dis. 2017;76(10):1648–1656. doi:10.1136/annrheumdis-2016-210802
- Flinn MA, Gennery AR. Adenosine deaminase deficiency: a review. Orphanet J Rare Dis. 2018;13(1):65. doi:10.1186/s13023-018-0807-5
- Meyts I, Aksentijevich I. Deficiency of Adenosine Deaminase 2 (DADA2): updates on the phenotype, genetics, pathogenesis, and treatment. J Clin Immunol. 2018;38(5):569–578. doi:10.1007/s10875-018-0525-8
- Barron KS, Aksentijevich I, Deuitch NT, et al. The spectrum of the deficiency of adenosine deaminase 2: an observational analysis of a 60 patient cohort. Front Immunol. 2021;12:811473. doi:10.3389/fimmu.2021.811473
- Signa S, Bertoni A, Penco F, et al. Adenosine Deaminase 2 Deficiency (DADA2): a crosstalk between innate and adaptive immunity. Front Immunol. 2022;13:935957. doi:10.3389/fimmu.2022.935957
- Cooray S, Omyinmi E, Hong Y, et al. Anti-tumour necrosis factor treatment for the prevention of ischaemic events in patients with deficiency of adenosine deaminase 2 (DADA2). Rheumatology (Oxford). 2021;60(9):4373–4378. doi:10.1093/rheumatology/keaa837
- Van Montfrans JM, Hartman EAR, Braun KPJ, et al. Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations. Rheumatology (Oxford). 2016;55(5):902–910. doi:10.1093/rheumatology/kev439